<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136108">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01823380</url>
  </required_header>
  <id_info>
    <org_study_id>8987</org_study_id>
    <nct_id>NCT01823380</nct_id>
  </id_info>
  <brief_title>Influence of the Vitamin D Blood Levels on the Amyotrophic Lateral Sclerosis Phenotype</brief_title>
  <official_title>Influence of the Vitamin D Blood Levels on the Amyotrophic Lateral Sclerosis Phenotype</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic lateral sclerosis is one of the most serious neurodegenerative disease, leading
      to death in 3 years by progressive paralysis of 4 limbs, speech, swallowing and breathing,
      and due to a progressive death of central and peripheral neurons. The cause of the disease
      is unknown, but an immunologically factor is more precisely suspected in ALS. Since 2008,
      the work of Immunology have shown that vitamin D was a major regulator of immunity. It
      regulates particularly the function of dendritic cells and regulates the immune response in
      macrophages. A vitamin D deficiency will induce activation of microglia. In neurology,
      vitamin D deficiency is associated with a greater impairment in neuronal function. This
      deficit is associated with a faster alteration of the microvasculature, alteration known to
      increase neuronal suffering and to enhance the neurodegenerative processes. The
      investigators postulate that ALS patients have a more severe prognosis if their vitamin D
      levels at the time of diagnosis is lower. The main objective of this study is to investigate
      the correlation between the rate of motor decline and blood levels of Vitamin D total.
      Secondary objectives are to investigate the relationship between blood levels of vitamin D
      and total disease duration of ALS, forced vital capacity, weight loss, age of onset and the
      start site of ALS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Vitamin D blood level</measure>
    <time_frame>the day of inclusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>The vitamine D blood level will be assessed the day of the inclusion of the patient.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Amyotrophic lateral sclerosis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood test</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Blood test</description>
    <arm_group_label>Amyotrophic lateral sclerosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject with possible, probable or definite Amyotrophic Lateral Sclerosis (ALS).

          -  ALS operating for less than three years at dosage of vitamin D time.

          -  Subject monitored in the center ALS of Montpellier for 6 months.

          -  Subject agreeing to give his consent in writing or orally if the patient SLA is
             unable to write

        Exclusion Criteria:

          -  Subject has received a Vitamine D treatment in the six months preceding the inclusion

          -  Subject with a clinical condition on the inclusion day that makes it highly probable
             death in the year (quadriplegic patient, subject ventilated for respiratory failure
             in ALS, major malnutrition) or with ALSFRS-R score &lt;20.

          -  Pregnant or breastfeeding women

          -  Subject not covered by a social security scheme.

          -  Subject under guardianship

          -  Adult protected by the law
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Camu, PU PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William Camu, PU PH</last_name>
    <email>w-camu@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>UH Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Chauveton, PU PH</last_name>
      <email>c-chauveton@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>William Camu, PU PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raoul Juntas-Morales, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Pageot, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>April 2, 2013</lastchanged_date>
  <firstreceived_date>March 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic lateral sclerosis</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Blood Levels</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
